Patent Yard Sign in
Expired Australian patentAustralia

Pharmaceutical combination for the treatment of prostatic hyperplasia containing a 5 alpha-reductase inhibitor and an antiandrogen

AU 1992017514 · Applicant: Merck & Co Inc

AusPat record

Overview

Drawings and full text

Its specification, documents and status are on IP Australia's AusPat.

Open the AusPat record

Read the whole patent

Listed from its IP Australia record in Patent Yard's archive of Australian patents past their term. Its claims, description and drawings are in the AusPat record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed March 19, 1992 and granted July 9, 1996. An Australian standard patent lasts 20 years from its date of patent, which is at most a year after this filing, so its term ended by March 19, 2013.
  • A pharmaceutical extension adds at most five years, so even that would have ended by March 19, 2018.
  • We check Australian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMarch 19, 1992
GrantedJuly 9, 1996
Term ended byMarch 19, 2013
Application numberAU 1992017514
Classification (IPC)A61K31/55 +2 more

Timeline

Timeline From IP Australia dates

1993199619992002200520082011Application filedMarch 19, 1992Patent grantedJuly 9, 1996Term ended byMarch 19, 2013

Sources & verification

Everything on this page comes from the IP Australia record linked above. Data from IP Australia's IPGOD, licensed under CC BY 2.5 AU.